Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants
- William Muller; Shabir Madhi; Beatriz Nuñez; Manuel Cots; Miroslava Bosheva; Ron Dagan
PMID: 37018470DOI: https://doi.org/10.1056/nejmc2214773
Access Resources
About
This letter to the editor describes the use of nirsevimab to prevent respiratory syncytial virus (RSV) in term and late-preterm infants. It includes contributions from various authors affiliated with institutions worldwide. The study is part of the MELODY Study Group's efforts to address childhood diseases and viral infections. The article focuses on safety, effectiveness, and acceptance of nirsevimab as a preventive treatment for RSV in different regions globally.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.